January 29 2019 Issue

1. Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement. 2. [What's Trending]: On tau protein and Alzheimer dementia symptoms. In the first segment, Dr. Jason Crowell talks with Dr. James Russell about his paper on brain death, the determination of brain death, and member guidance for brain death accommodation requests. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Matthew Brier on tau protein and Alzheimer dementia symptoms.DISCLOSURES: Dr. Jason Crowell reports no disclosures. Dr. James Russell has served on Scientific Advisory Boards for Cytokinetics - Data Monitoring Board PROTOCOL CY 5022 A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE- RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS). Dr. James Russell received travel funding from 1) Non-profit - Mexican Academy of Neurology - Funded travel and lodging to speak at Annual Meeting Nov 2018 - no honorarium (2) Non-profit - ALS Association - funded travel and lodging to do site visit for ALSA certification of UVA ALS Clinic. Dr. James Russell has publishing royalties from (1) Neuromuscular Disorders, McGraw-Hill, 2nd edition published 2015, with subsequent royalities 2) Honorarium for published article in Continuum: Approach to peripheral neuropathy. Continuum: Peripheral Nervous System Disorders. Fall 2017. Dr. James Russell has done consultancies with compensation for market research interviews regarding ALS therapeutics and is currently being compensated for expert opinion in two medical legal cases, one in support of the defendant and one in support of the plaintiff. Dr. Matthew Brier has received funding for Biogen, travel and accommodation and received research support for Medical Scientist Training Program Grant to WUSTL (5T32GM007200-37.